Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine

Vaccine

Volumn 28, Issue 33, 2010, Pages 5491-5496

  de Matos Guedes, Herbert Leonel ^a,b   Pinheiro, Roberta Olmo ^a   Chaves, Suzana Passos ^a   De Simone, Salvatore Giovanni ^a,b   Rossi Bergmann, Bartira ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cysteine proteases; Leishmania amazonensis; Leishmaniasis; Serine proteases; Vaccine

Indexed keywords

ANTILEISHMANIAL AGENT; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 4; LEISHMANIA AMAZONENSIS ANTIGEN; LEISHMANIA VACCINE; PARASITE ANTIGEN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BAGG ALBINO MOUSE; COMPETITIVE INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ISOLATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IN VITRO STUDY; INFECTION PREVENTION; INFECTION SENSITIVITY; LEISHMANIA; LEISHMANIASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTECTION; SKIN ALLERGY; SKIN SENSITIZATION; VACCINATION;

ANIMALS; CYSTEINE PROTEINASE INHIBITORS; CYTOKINES; LEISHMANIA; LEISHMANIASIS; LEISHMANIASIS VACCINES; MICE; MICE, INBRED BALB C; PROTOZOAN PROTEINS; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS;

EID: 77955054536     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.04.109     Document Type: Article

References (42)

1. WHO. Report on the scientific working group on leishmaniasis; 2004. http://www.who.int/tdr.
2. Khamesipour A., Dowlati Y., Asilian A., Hashemi-Fesharki R., Javadi A., Noazin S., et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005, 23:3642-3648.
3. Noazin S., Khamesipour A., Moulton L.H., Tanner M., Nasseri K., Modabber F., et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis-a meta-analysis. Vaccine 2009, 27:4747-4753.
4. Velez I.D., Gilchrist K., Arbelaez M.P., Rojas C.A., Puerta J.A., Antunes C.M., et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 2005, 99:593-598.
5. De Luca P.M., Mayrink W., Alves C.R., Coutinho S.G., Oliveira M.P., Bertho A.L., et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine 1999, 17:1179-1185.
6. Kenney R.T., Sacks D.L., Sypek J.P., Vilela L., Gam A.A., Evans-Davis K. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999, 163:4481-4488.
7. Pinheiro R.O., Pinto E.F., Lopes J.R.B., de Matos Guedes H.L., Fentanes R.F., Rossi-Bergmann B. TGF-β-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens. Microb Infect 2005, 7:1317-1323.
8. Launois P., Maillard I., Pingel S., Swihart K.G., Xenarios I., Acha-Orbea H., et al. IL-4 rapidly produced by V beta 4V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity 1997, 6:541-549.
9. Mitchell G.F., Handman E. The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease-promoting antigen in murine cutaneous leishmaniasis. Parasite Immunol 1986, 8:255-263.
10. Tolson D.L., Jardim A., Schnur L.F., Stebeck C., Tuckey C., Beecroft R.P., et al. The kinetoplastid membrane protein 11 of Leishmania donovani and African trypanosomes is a potent stimulator of T-lymphocyte proliferation. Infect Immun 1994, 62:4893-4899.
11. Pinheiro R.O., Pinto E.F., Benedito A.B., Lopes U.G., Rossi-Bergmann B. The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis. An Acad Bras Cienc 2004, 76:519-527.
12. Mottram J.C., Coombs G.H., Alexander J. Cysteine peptidases as virulence factors of Leishmania. Curr Opin Microbiol 2004, 7:375-381.
13. Yao C., Donelson J.E., Wilson M.E. The major surface protease (MSP or GP63) of Leishmania sp. biosynthesis, regulation of expression, and function. Mol Biochem Parasitol 2003, 132:1-16. Review.
14. Buxbaum L.U., Denise H., Coombs G.H., Alexander J., Mottram J.C., Scott P. Cysteine protease B of Leishmania mexicana inhibits host Th1 responses and protective immunity. J Immunol 2003, 171:3711-3717.
15. de Matos Guedes H.L., Rezende-Neto J.M., Abreu M.F., de Salles C.M.C., De-Simone S.G. Identification of serine proteases from Leishmania braziliensis. Z Naturforsch C 2007, 62:373-381.
16. Silva-Lopez R.E., De-Simone S.G. Leishmania (Leishmania) amazonensis: purification and characterization of a promastigote serine protease. Exp Parasitol 2004, 107:173-182.
17. Silva-Lopez R.E., De-Simone S.G. A serine protease from detergent soluble extract of Leishmania (Leishmania) amazonensis. Z Naturforsch 2004, 59:590-598.
18. Silva-Lopez R.E., Coelho M.G.P., De-Simone S.G. Purification of an extracellular serine protease from Leishmania (Leishmania) amazonensis. Parasitology 2005, 131:1-13.
19. O'Daly J.A., Cabrera Z. Immunization of hamsters with TLCK-killed parasites induces protection against Leishmania infection. Acta Trop 1986, 43:225-236.
20. Rossi-Bergmann B., Lenglet A., Bezerra-Santos C.R., Costa-Pinto D., Traub-Czeko Y.M. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem I Oswaldo Cruz 1999, 94:74.
21. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27(12):1787-1796.
22. Richerson H.B., Dvorak H.F., Leskowitz S. Cutaneous basophil hypersensitivity. I. A new look at the Jones-Mote reaction, general characteristics. J Exp Med 1970, 132:546-557.
23. Liew F.Y., Dhaliwal J.S. Distinctive cellular immunity in genetically susceptible BALB/c mice recovered from Leishmania major infection or after subcutaneous immunization with killed parasites. J Immunol 1987, 138:4450-4456.
24. Scott P. Immunologic memory in cutaneous leishmaniasis. Cell Microbiol 2005, 7:1707-1713.
25. Pinheiro R.O., Rossi-Bergmann B. Interferon-gamma is required for the late but not early control of Leishmania amazonensis infection in C57Bl/6 mice. Mem Inst Oswaldo Cruz 2007, 102:79-82.
26. Hernández M.X., Barçante T.A., Vilela L., Tafuri W.L., Afonso L.C., Vieira L.Q. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunol Lett 2006, 105:38-47.
27. Salomão R, Castelo-Filho A, Medeiros IM, Sicolo MA. Plasma levels of tumor necrosis factor-a in patients with visceral leishmaniasis (Kala-Azar). Association with activity of the disease and clinical remission following antimonial therapy. Rev. Inst. Med. trop. São Paulo; 1996 38:113-18.
28. Gomes D.C., Pinto E.F., de Melo L.D., Lima W.P., Larraga V., Lopes U.G., et al. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine 2007, 25:2168-2172.
29. Carvalho L.P., Pearce E.J., Scott P. Functional dichotomy of dendritic cells following interaction with Leishmania braziliensis: infected cells produce high levels of TNF-alpha, whereas bystander dendritic cells are activated to promote T cell responses. J Immunol 2008, 181:6473-6480.
30. Okwor I., Liu D., Beverley S.M., Uzonna J.E. Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. Proc Natl Acad Sci USA 2009, 106:13951-13956.
31. Ji J., Masterson J., Sun J., Soong L. CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonensis infection. J Immunol 2005, 174:7147-7153.
32. Chapman M.D., Wünschmann S., Pomés A. Proteases as Th2 adjuvants. Curr Allergy Asthma Rep 2007, 7:363-367.
33. Sokol C.L., Chu N.Q., Yu S., Nish S.A., Laufer T.M., Medzhitov R. Basophils function as antigen-presenting cells for an allergen-induced T helper type 2 response. Nat Immunol 2009, 10:713-720.
34. Perrigoue J.G., Saenz S.A., Siracusa M.C., Allenspach E.J., Taylor B.C., Giacomin P.R., et al. MHC class II-dependent basophil-CD4+ T cell interactions promote T(H)2 cytokine-dependent immunity. Nat Immunol 2009, 10:697-705.
35. Yoshimoto T., Yasuda K., Tanaka H., Nakahira M., Imai Y., Fujimori Y., et al. Basophils contribute to T(H)2-IgE responses in vivo via IL-4 production and presentation of peptide-MHC class II complexes to CD4+ T cells. Nat Immunol 2009, 10:706-712.
36. Wynn T.A. Basophils trump dendritic cells as APCs for T(H)2 responses. Nat Immunol 2009, 10:679-681.
37. Ivens A.C., Peacock C.S., Worthey E.A., Murphy L., Aggarwal G., Berriman M., et al. The genome of the kinetoplastid parasite Leishmania major. Science 2005, 309:436-442.
38. Colmenares M., Tiemeyer M., Kima P., McMahon-Pratt D. Biochemical and biological characterization of the protective Leishmania pifanoi amastigote antigen P-8. Infect Immun 2001, 69:6776-6784.
39. Rafati S., Ghaemimanesh F., Zahedifard F. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, protein/protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice. Vaccine 2006, 12:3290-3297.
40. de Matos Guedes H.L., Carneiro M.P.D., Gomes D.C.O., Rossi-Bergmann B., De-Simone S.G. Oligopeptidase B from Leishmania amazonensis: molecular cloning, gene expression analysis and molecular model. Parasitol Res 2007, 101. 865.875.
41. Caler E.V., Vaena De Avalos S., Haynes P.A., Andrews N.W., Burleigh B. Oligopeptidase B-dependent signaling mediates host cell invasion by Trypanosoma cruzi. Embo J 1998, 17:4975-4986.
42. de Matos Guedes H.L., de Carvalho R.S.N., Gomes D.C.O., Rossi-Bergmann B., De-Simone S.G. Oligopeptidase B-2 from Leishmania amazonensis with an unusual C-terminal extension. Acta Parasitol 2008, 53:197-204.